Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, announced first-in-human data for LFD-200, its novel subcutaneously administered ADC delivering a potent glucocorticoid directly to immune cells. The data were presented at EULAR 2026, the European Congress of Rheumatology, held in London, UK, from June 3-6, 2026.
The Phase 1 study in healthy participants showed that LFD-200 was well tolerated and demonstrated dose-responsive anti-inflammatory activity with no impact on serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity. This finding is significant because systemic glucocorticoids, while effective, are associated with serious side effects such as adrenal suppression, osteoporosis, and increased infection risk. By targeting delivery to immune cells, LFD-200 aims to maximize therapeutic benefit while minimizing systemic exposure.
Dosing of patients with moderate to severe rheumatoid arthritis (RA) in the Phase 1 study is ongoing, with data expected by year-end 2026. The company highlighted that these initial results support further development of LFD-200 as a potential treatment for RA and other autoimmune conditions.
Lifordi leverages the success of ADCs, a modality proven in oncology, to treat autoimmune and inflammatory diseases. LFD-200 is the company's lead candidate, and it has also applied its drug delivery approach to other payloads, including antisense oligonucleotides, siRNA, and small molecules. The company is backed by investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures.
The full announcement and additional details are available at the Lifordi website.
